busulfan

P1/2, N=10, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Enrolling by invitation --> Recruiting

P=N/A, N=37, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University

Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287.).

P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678.).

P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

P2, N=82, Not yet recruiting, Nantes University Hospital | N=60 --> 82

P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Mar 2031 --> Jun 2031 | Trial primary completion date: Mar 2031 --> Jun 2031

Brentuximab vedotin led to partial response and high-dose chemotherapy combined with autologous HSCT was performed...After cessation of alectinib, allogeneic bone marrow transplantation from an HLA 1-locus mismatched unrelated donor was performed after conditioning with fludarabine, busulfan, and total body irradiation. GVHD prophylaxis consisted of tacrolimus and short-term methotrexate...The lymphoma has not recurred for 2 years after allo-HSCT without resuming alectinib. The clinical course of our case suggests that alectinib bridging therapy and allo-HSCT are effective in relapsed/refractory ALK-positive ALCL.

P1/2, N=10, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Enrolling by invitation

P2, N=60, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

P2, N=260, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

P2, N=23, Not yet recruiting, Northside Hospital, Inc.

P2, N=50, Recruiting, Peking University People's Hospital | Unknown status --> Recruiting | Trial completion date: Sep 2021 --> Sep 2025 | Trial primary completion date: Sep 2021 --> Sep 2025

P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P1/2, N=10, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID)

P1, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

To better understand the migration of these cells and possibly influence their migration, NSG mice were conditioned with agents to clear BM cellular compartments, i.e., busulfan or total body irradiation (TBI), or promote T-cell migration to inflamed BM, i.e., incomplete Freund's adjuvant (IFA), prior to administering γδ T cells...Using an established neuroblastoma NSG mouse model, we show that intratumorally-injected γMSCs increase the homing of γδ T cells to this tumor. These studies provide insight into the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells in NSG mice, which is critical to understanding the fundamental properties of these cells.

P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

Cladribine plus BuCy intensive conditioning regimen before allo-HSCT exhibits favorable treatment efficacy with acceptable toxicity in R/R AML patients.

Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the five-drug combination, suggesting a clinical relevance. The results provide a rationale for clinical trials using these two- and five-drug combinations as part of a conditioning regimen for AML patients undergoing HSCT.

P1, N=31, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting

P2, N=9, Terminated, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Mar 2024; Low accrual

P1/2, N=40, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2024 --> Dec 2032 | Trial primary completion date: Dec 2024 --> Dec 2032

In the future, clinical applications should bring higher benefits. Since SVF is the patient's own tissue, being harmless, it will offer an advantageous supportive treatment option for patients already weakened by cancer and anticancer therapy.

This study shows that PFA exerts a protective effect against testicular damage by attenuating OS induced by busulfan. Our results suggest that PFA is a potentially relevant drug used to decrease the side effects induced by busulfan on testicular function and sperm during cancer chemotherapy.

P2, N=61, Active, not recruiting, Fred Hutchinson Cancer Center | N=99 --> 61

P2, N=75, Active, not recruiting, Children's Hospital of Philadelphia | Recruiting --> Active, not recruiting

P=N/A, N=44, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=20 --> 44

P1, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2027 --> Apr 2025 | Trial primary completion date: Feb 2027 --> Apr 2025

P1, N=3, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=12, Recruiting, ExCellThera inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Jun 2026

P2, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

Women undergoing allo-HSCT are at higher risk of HPV infection and premalignant lesions, and consequently, screening programs should be strictly followed- However, pathologists should be aware of the cytological abnormalities associated with busulfan, which may closely mimic HPV-associated lesions.

Our findings demonstrate that busulfan treatment is a beneficial alternative for simple and efficient PBMC engraftment in a rodent model, possibly helping to evaluate human immunity in preclinical studies.

P=N/A, N=139, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: May 2024 --> May 2025

P2, N=60, Not yet recruiting, Nantes University Hospital

Most adverse events/reactions were related to disease background, busulfan conditioning or immune reconstitution; the safety profile of the real world experience was in line with premarketing cohort...These long-term data suggest that the risk-benefit of GT in ADA remains favorable and warrant for continuing long-term safety monitoring. Clinical trial registration: NCT00598481 , NCT03478670 .

P1, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P2, N=103, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P2, N=144, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025